Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antipsychotic medication |
| gptkbp:approvalYear |
2002
|
| gptkbp:ATCCode |
gptkb:N05AX12
|
| gptkbp:availableOn |
gptkb:tablet
oral solution disintegrating tablet injectable suspension |
| gptkbp:brand |
gptkb:Abilify
|
| gptkbp:CASNumber |
129722-12-9
|
| gptkbp:chemicalFormula |
C23H27Cl2N3O2
|
| gptkbp:contraindication |
hypersensitivity to aripiprazole
|
| gptkbp:developedBy |
gptkb:Otsuka_Pharmaceutical
|
| gptkbp:drugClass |
antipsychotic medication
|
| gptkbp:eliminationHalfLife |
75 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:firstSynthesized |
1988
|
| https://www.w3.org/2000/01/rdf-schema#label |
aripiprazole
|
| gptkbp:KEGGID |
D07441
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
antagonist at serotonin 5-HT2A receptor
partial agonist at dopamine D2 receptor partial agonist at serotonin 5-HT1A receptor |
| gptkbp:MedlinePlusID |
a603012
|
| gptkbp:metabolism |
liver (CYP2D6, CYP3A4)
|
| gptkbp:molecularWeight |
448.38 g/mol
|
| gptkbp:patentExpired |
2014 (US)
|
| gptkbp:pregnancyCategory |
C (US)
B3 (Australia) |
| gptkbp:proteinBinding |
99%
|
| gptkbp:PubChem_CID |
60795
CHEMBL111 DB01238 |
| gptkbp:riskFactor |
suicidal thoughts
extrapyramidal symptoms neuroleptic malignant syndrome |
| gptkbp:routeOfAdministration |
oral
intramuscular injection |
| gptkbp:sideEffect |
nausea
anxiety headache weight gain restlessness insomnia tardive dyskinesia akathisia |
| gptkbp:UNII |
82VFR53I78
|
| gptkbp:usedFor |
bipolar disorder
schizophrenia Tourette syndrome irritability associated with autism major depressive disorder (adjunct) |
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:bfsParent |
gptkb:CYP3A4
|
| gptkbp:bfsLayer |
5
|